Amgen's Q2 2016 earnings call highlighted continued strong performance, with revenue and EPS exceeding expectations.  Management expressed confidence in the company's long-term strategy, with a notable increase in guidance for 2016 revenue and EPS, driven by positive product launches and strong performance in growth brands.  This, combined with the aggressive share repurchase program, suggests a positive outlook for the short-term and potentially the next two weeks, as investors likely respond favorably to the increased guidance.
[1]
